CRSP financials
CRISPR Therapeutics (CRSP) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
CRSP income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $3.51M | -$229.45M | -$568.32M | -$581.60M | -6.47 |
| 2024 | $35.00M | -$75.25M | -$466.57M | -$366.25M | -4.34 |
| 2023 | $370.00M | $239.75M | -$222.54M | -$153.61M | -1.94 |
| 2022 | $436.00K | -$109.81M | -$673.16M | -$650.17M | -8.36 |
| 2021 | $913.08M | $811.90M | $373.53M | $377.66M | 4.70 |
| 2020 | $719.00K | -$268.69M | -$354.44M | -$348.87M | -5.29 |
- CRSP revenue was $3.51M in fiscal 2025, net income -$581.60M.
Updated 2026-11-03 01:00 UTC